CD8A and neoplasm: They found that MEK inhibition prevented intra-tumoral CD8+ T-cells from TCR-stimulated death without affecting their cytolytic activity, and MEK inhibitor G-38963 exhibited a synergistic effect with anti-PD-L1 therapy on tumor regression [168].